Updated Results of a Phase 1a Trial of STAR-0215 for Hereditary Angioedema

STAR-0215 is an investigational extended half-life monoclonal antibody for hereditary angioedema (HAE). This trial (NCT05477160) assesses STAR-0215's potential for safe and durable suppression of HAE attacks after single doses in healthy subjects.

Source: Journal of Allergy and Clinical Immunology - February 1, 2024 Category: Allergy & Immunology Authors: William Lumry, Christopher Morabito, Theodora Cohen, Michele Gunsior, Kristine Bernard, Pamela Gustafson Source Type: research